Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 38

2.

Role of statins for the primary prevention of cardiovascular disease in patients with type 2 diabetes mellitus.

Riche DM, McClendon KS.

Am J Health Syst Pharm. 2007 Aug 1;64(15):1603-10. Review.

PMID:
17646562
3.

Cumulative clinical trial data on atorvastatin for reducing cardiovascular events: the clinical impact of atorvastatin.

Bybee KA, Lee JH, O'Keefe JH.

Curr Med Res Opin. 2008 Apr;24(4):1217-29. doi: 10.1185/030079908X292001 . Epub 2008 Mar 20. Review.

PMID:
18358084
5.
6.
7.

[Thoughts about the results of the "IDEAL" study].

Kalina A.

Orv Hetil. 2006 May 28;147(21):993-5. Review. Hungarian.

PMID:
16812974
8.

What does the future hold for diabetic dyslipidaemia?

Crespin SR.

Acta Diabetol. 2001;38 Suppl 1:S21-6. Review.

PMID:
11829450
9.

Clinical trials and lipid guidelines for type II diabetes.

Prisant LM.

J Clin Pharmacol. 2004 Apr;44(4):423-30. Review.

PMID:
15051751
10.

Intensified multifactorial intervention and cardiovascular outcome in type 2 diabetes: the Steno-2 study.

Pedersen O, Gaede P.

Metabolism. 2003 Aug;52(8 Suppl 1):19-23. Review.

PMID:
12939735
11.

Atorvastatin and cardiovascular protection: a review and comparison of recent clinical trials.

Ray KK, Cannon CP.

Expert Opin Pharmacother. 2005 Jun;6(6):915-27. Review.

PMID:
15952920
13.

Prevention of coronary heart disease in type 2 diabetes.

Mykkänen L.

Int J Clin Pract Suppl. 2000 Oct;(113):40-5. Review.

PMID:
11965831
15.

Different time course for prevention of coronary and stroke events by atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA).

Sever PS, Poulter NR, Dahlöf B, Wedel H; Anglo-Scandinavian Cardiac Outcomes Trial Investigators.

Am J Cardiol. 2005 Sep 5;96(5A):39F-44F. Review.

PMID:
16126022
16.

Framingham score and microalbuminuria: combined future targets for primary prevention?

Asselbergs FW, Hillege HL, van Gilst WH.

Kidney Int Suppl. 2004 Nov;(92):S111-4. Review.

17.

Insulin resistance implications for type II diabetes mellitus and coronary heart disease.

Haffner SM, Miettinen H.

Am J Med. 1997 Aug;103(2):152-62. Review.

PMID:
9274899
18.

Pharmacokinetic evaluation of atorvastatin and sitagliptin in combination for the treatment of type 2 diabetes.

Scheen AJ.

Expert Opin Drug Metab Toxicol. 2012 Jun;8(6):745-58. doi: 10.1517/17425255.2012.686603. Epub 2012 May 16. Review.

PMID:
22587686
19.

Reducing the cardiovascular consequences of diabetes mellitus.

Passa P.

Diabet Med. 1998;15 Suppl 4:S69-72. Review.

PMID:
9868997
20.

Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials.

Costa J, Borges M, David C, Vaz Carneiro A.

BMJ. 2006 May 13;332(7550):1115-24. Epub 2006 Apr 3. Review.

Supplemental Content

Support Center